AgomAb Therapeutics Identifies Regenerative Pathway Modulators, Attracts Investors
HGF Mimetic Agonistic Antibody Under Development
Two US VCs have led a large $75m series B financing of Belgium’s AgomAb Therapeutics, which is gaining traction in developing antibodies that act on the HGF-MET pathway, potentially reversing fibrosis and allowing damaged tissues to regain function.
